SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is a major talking point following its robust earnings and impressive future guidance, which many in the community are heralding as the start of a "memory supercycle" fueled by relentless AI demand. While bullish sentiment is high, a significant portion of the market remains cautious, drawing parallels to recent post-earnings dips in other tech stocks, and questioning if the strong results can buck the broader market's skeptical reaction.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending amidst fervent community excitement, with many enthusiastically discussing its potential for significant upside as a Solana-based meme coin. The conversation highlights its deep connection to cannabis culture, emphasizing it as a 'culture coin' poised for growth.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Processa Pharmaceuticals (PCSA) is experiencing explosive trading volume and multiple halts following positive Phase 2 clinical data for its breast cancer treatment. The community is sharply divided, with bulls aggressively pushing for further parabolic gains, citing its low float, while skeptics point to a recent reverse stock split and concerns over potential dilution and manipulation amidst extreme price volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer Inc. is trending lower amid intense community debate, as many investors express a lack of trust in its management and question the execution despite solid revenue outlooks and confirmed AI deals. While some see the sharp pullback as an oversold buying opportunity, others are critical of the leadership and point to broader market skepticism towards the AI sector. The ongoing discussion centers on whether the current valuation reflects underlying fundamentals or alleged market manipulation.

Mega Fortune Co., Ltd. operates as an investment holding company. It specializes in delivering comprehensive IoT solutions and services across various industries. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited (MGRT), a recent Hong Kong IPO with a low float, is trending with extreme volatility and multiple trading halts, prompting intense community discussion. Many are comparing it to other rapidly soaring 'China concept stocks' like ANPA, speculating on its potential for further massive gains and a short squeeze. Conversely, a significant portion of the conversation warns of it being a high-risk 'pump and dump' or 'Chinese scam,' urging caution and prompt profit-taking amidst its unpredictable price swings.

Solo Brands, Inc. sells online outdoor products. Its products include Solo Stove firepits, stoves, and accessories, Chubbies apparel, Oru Kayak, a folding portable kayak, and Isle paddle boards. The company was founded in 2011 and is headquartered in Grapevine, TX.

Solo Brands Inc - Ordinary Shares - Class A

Solo Brands (SBDS) is trending as community discussion intensely focuses on its exceptionally low share float, fueling widespread speculation about an impending short squeeze. Traders are actively accumulating positions, anticipating a rapid, high-volume surge driven by the stock's thin availability. The sentiment suggests strong belief in a significant upward move, drawing comparisons to other recent micro-float runners.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors debate the impact of its lawsuit against alleged stock manipulators, alongside anticipation for its CEO's fireside chat and a new bullish analyst rating from Cantor Fitzgerald. The community remains divided, with frustrated shareholders seeking clarity on buybacks and stock performance, while long-term bulls emphasize the company's significant AI infrastructure contracts and deep undervaluation relative to its sector amid broader market volatility.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies (AMPX) is trending amidst significant market volatility, with its stock experiencing daily swings that frustrate many short-term traders. Despite these price movements, the community remains largely bullish, actively discussing the recent expansion of its Korea Battery Alliancea strategic move poised to dramatically increase production capacity for its high-energy-density silicon anode batteries. This increased manufacturing capability and recent Nokia integration are seen as key steps towards fulfilling anticipated demand in the rapidly growing drone and electric aviation sectors, with many investors viewing current pullbacks as a prime accumulation opportunity for long-term growth.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is actively trending following significant advancements in institutional digital asset adoption, highlighted by J.P. Morgan's recent commercial paper issuance on the Solana blockchain and a new tokenization partnership with State Street. Bulls are pointing to these developments and positive analyst price targets, alongside the long-term potential of its Helios data center business benefiting from ERCOT grid upgrades, as strong tailwinds. However, a segment of the community remains concerned about the company's past Solana investments and broader market sentiment regarding a potential 'AI and crypto bubble' bursting.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals (BCRX) is a major talking point after receiving FDA approval for its ORLADEYO oral pellets, establishing it as the first oral prophylactic treatment for hereditary angioedema in young children. Despite this positive catalyst and ongoing merger developments, community sentiment is largely frustrated by the persistent share price stagnation, with many accusing market manipulation and relentless short selling. Investors are closely scrutinizing the company's valuation against its commercial success and pipeline, anticipating that future events like the Astria Therapeutics acquisition or potential management shifts could finally drive a sustained re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Shares opened well above the offer price, valuing the company at roughly $47 billion after an upsized offering.</li><li>Proceeds are largely being used to reduce debt, with private equity backers partially exiting through the sale.</li><li>The debut marks the largest U.S. IPO since 2021, signaling renewed appetite for large public listings.</li></ul><p>Medline (MDLN) shares surged nearly 30% on Wednesday in their first day of trading, marking a blockbuster debut for the medical-supplies company after it raised $6.26 billion in the largest initial public offering of 2025.</p><p>The stock opened at $35 a share, well above its IPO price of $29, giving Medline a market value of about $47 billion based on shares outstanding disclosed in regulatory filings.</p><h2 class="st-heading-2"><strong>New High For 2025 IPOs</strong></h2><p>Medline sold roughly 216 million shares in an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/medical-supply-giant-medline-upsizes-ipo-and-sets-29-price-ahead-of-wednesday-nasdaq-debut/cLeJprcREpi">upsized offering</a> priced at $29 a share, after increasing the deal size from its earlier filing.</p><p>The IPO surpasses the previous largest listing of the year, a $5.26 billion Hong Kong offering by China’s Contemporary Amperex Technology, and marks the biggest U.S. IPO since Rivian Automotive’s $13.7 billion debut in 2021.</p><h2 class="st-heading-2"><strong>Backers And Use Of Proceeds</strong></h2><p>The company counts Blackstone, Carlyle Group and Hellman &amp; Friedman among its major shareholders.</p><p>Medline said most of the proceeds from newly issued shares will be used to reduce debt and strengthen its balance sheet, with the remainder allocated to general corporate purposes and offering-related expenses. Proceeds from shares sold by existing holders will go toward buying out equity interests from certain pre-IPO owners.</p><h2 class="st-heading-2"><strong>A Medical Supply Giant At Scale</strong></h2><p>Medline describes itself as the largest provider of medical-surgical products and supply-chain services by net sales. Its catalog includes roughly 335,000 products used across hospitals, surgery centers, physicians’ offices and post-acute care facilities.</p><p>About one-third of Medline’s branded products are manufactured in-house across 33 facilities, while the rest are sourced from more than 500 suppliers in around 40 countries. The company also distributes about 145,000 third-party products through its supply-chain services business.</p><h2 class="st-heading-2"><strong>Financial Performance</strong></h2><p>Medline posted $20.6 billion in net sales and $1 billion in profit for the first nine months of 2025. This came after the company reported $25.5 billion in revenue and $1.2 billion in net income in 2024. The company reported that sales have grown annually since its inception and is helped by recurring revenue from long-term customer contracts.</p><p>Prime Vendor agreements, which designate Medline as a primary supplier, generated $16 billion in net sales in 2024. The company said retention under those contracts has averaged more than 98% over the past five years.</p><h2 class="st-heading-2"><strong>IPO Momentum Builds</strong></h2><p>Medline’s strong debut comes as Wall Street attention increasingly turns to the next wave of mega listings. Markets have been buzzing for more than a week around expectations that&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/will-spacex-ticker-be-mars-spax-or-sex-polymarket-bets-reveal-odds/cLeO1qrREq9">SpaceX could go public</a> at a valuation of roughly $1.5 trillion, which would make it the largest IPO in history, potentially in mid-to-late 2026.&nbsp;</p><p>SpaceX CEO Elon Musk earlier this week indicated that media reports around the aerospace company’s IPO plans are accurate.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Medline was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:975/149;" src="https://news.stocktwits-cdn.com/mdln_ss_png_91dc8d27a6.webp" alt="mdln ss.png" width="975" height="149"><figcaption>MDLN sentiment and message volume as of December 17| Source: Stocktwits</figcaption></figure><p>One user said, “lezgo! Bought $10K @ $36.62. Let's see where this takes us.”&nbsp;</p><p><stembedurl>https://stocktwits.com/jvbiotek/message/639462113</stembedurl></p><p>Another user predicted that “this share will keep raising, medical equipments are essential business.”&nbsp;</p><p><stembedurl>https://stocktwits.com/x828282/message/639461407</stembedurl></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Medline logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Medline Stock Soars In Debut As Medical Supply Giant Seals 2025’s Biggest IPO

The company's first day on the market underscored strong investor demand for scaled, profitable issuers as the U.S. IPO pipeline shows strength.

Equity

<ul class="summary-bullets"><li>Share count increased from the preliminary filing, with underwriters also granted an option for additional shares.</li><li>Proceeds are earmarked largely for debt repayment and balance sheet strengthening.</li><li>The company enters public markets backed by steady revenue growth and long-term customer contracts.</li></ul><p>Medline Inc. (MDLN) said it has priced its upsized initial public offering at $29 a share after increasing the share count from its earlier filing, clearing the way for the medical-supplies giant to debut on the Nasdaq Global Select Market on Wednesday.</p><p>The company will offer about 216 million Class A shares, up from the 179 million shares outlined in its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/medline-files-for-one-of-2025-s-largest-ip-os-with-potential-valuation-near-55-3-b/cLIpTkjREmU">preliminary filing last week</a>, and has granted underwriters a 30-day option to purchase up to an additional 32.4 million shares. The IPO is expected to close on Thursday.</p><h2 class="st-heading-2"><strong>Use Of Proceeds</strong></h2><p>Medline said most of the proceeds from the IPO will go toward strengthening its balance sheet. The company plans to use the net proceeds from 179 million newly issued shares to repay outstanding debt under its senior secured term loan facilities, with the rest earmarked for general corporate purposes and offering-related expenses.</p><p>Proceeds from another 37 million shares, along with any shares sold if underwriters exercise their option, will be used to buy out an equivalent number of equity interests from certain pre-IPO owners.</p><h2 class="st-heading-2"><strong>Medical Supply Giant At Scale</strong></h2><p>Medline describes itself as the largest provider of medical-surgical products and supply chain services by net sales. Its product catalog spans about 335,000 items used across hospitals, surgery centers, doctors’ offices and post-acute care facilities.</p><p>About one-third of Medline’s branded products are made in-house at 33 manufacturing facilities. The rest are sourced from more than 500 suppliers across roughly 40 countries. Through its Supply Chain Solutions segment, Medline also distributes about 145,000 third-party products and offers inventory and logistics support to customers.</p><h2 class="st-heading-2"><strong>Prime Vendor Relationships Underpin Sales</strong></h2><p>Medline generated $20.6 billion in net sales and $1 billion in profit over the first nine months of 2025, along with $2.7 billion in core profit. In 2024, the company brought in $25.5 billion in revenue and $1.2 billion in net income. Medline said its sales have grown every year since the company was founded, supported by a large base of recurring revenue.</p><p>Prime Vendor agreements, which are long-term contracts under which Medline serves as a primary supplier of medical products, accounted for $16 billion in net sales in 2024. Medline said its Prime Vendor retention rate has averaged more than 98% over the past five years.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Medline was ‘neutral’ amid ‘normal’ message volume.</p><figure class="image"><img style="aspect-ratio:972/146;" src="https://news.stocktwits-cdn.com/mdln_ss_png_4ccf6a94d8.webp" alt="mdln ss.png" width="972" height="146"><figcaption>MDLN sentiment and message volume as of December 16| Source: Stocktwits</figcaption></figure><p>One user said they likely wouldn’t get their pre-IPO order filled at $30, calling the price too high.</p><p><stembedurl>https://stocktwits.com/six0nine/message/639373037</stembedurl></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

Medical Supply Giant Medline Upsizes IPO And Sets $29 Price Ahead of Wednesday Nasdaq Debut

The IPO features an expanded share count, with proceeds directed toward debt reduction and corporate needs.

<ul class="summary-bullets"><li>Medline plans to sell 179 million Class A shares at $26 to $30 each.</li><li>Major institutional investors signaled interest in buying as much as $2.35 billion of stock.</li><li>Proceeds will be used to buy units of Medline Holdings LP and support debt repayment.</li></ul><p>Medline Inc. (MDLN) set the stage for a major market debut, unveiling a preliminary IPO filing for 179 million Class A shares at an expected price range of $26 to $30.</p><p>The filing did not include a valuation, but Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/medical-supply-firm-medline-aims-raise-54-billion-us-ipo-2025-12-08/">reported</a> the deal could reach $55.3 billion, potentially making it 2025’s biggest IPO. The blockbuster listing is also expected to serve as a key test of investor appetite as markets move toward 2026.</p><p>Underwriters have a 30-day option to buy an additional 26.85 million shares. Members of the Mills family and their affiliates have indicated interest in purchasing as much as $250 million of stock at the offering price. A group of institutional investors including Baillie Gifford, Capital Research, Counterpoint Global, Durable Capital, GIC, Janus Henderson, Viking Global and WCM Investment Management have expressed interest in purchasing up to $2.35 billion of shares.&nbsp;</p><h2 class="st-heading-2"><strong>Use Of Proceeds&nbsp;</strong></h2><p>Medline plans to use the proceeds from the offering to buy newly issued common units from Medline Holdings LP.&nbsp;</p><p>Medline Holdings LP is the operating partnership that owns the business, and Medline Inc. will sit above it as the public company. After the IPO, Medline will have two types of stock, Class A and Class B, and both will carry one vote each. Existing owners hold partnership units in Medline Holdings LP, so they will receive the same number of Class B shares to match those units.</p><p>Medline Holdings will use the funds for debt repayment, general corporate purposes and to cover offering expenses. Any additional proceeds from an underwriter option exercise will be used to buy or redeem equity holdings from certain pre-IPO owners.</p><h2 class="st-heading-2"><strong>Medline’s Supply And Delivery Network</strong></h2><p>Medline describes itself as the largest provider of medical-surgical products and supply chain services based on total net sales. The company’s catalog spans roughly 335,000 medical products used in hospitals, surgery centers, doctors’ offices and post-acute care settings. Medline runs 69 distribution centers worldwide, including 45 in the U.S., with more than 29 million square feet of warehouse space. The network is large enough to provide next-day delivery to about 95% of its U.S. customers.</p><p>Medline manufactures about one-third of its branded products in 33 facilities and sources the rest from more than 500 suppliers across about 40 countries. The company’s Supply Chain Solutions segment distributes 145,000 third-party products and provides inventory and logistics optimization services.</p><h2 class="st-heading-2"><strong>Prime Vendor Relationships Underpin Sales</strong></h2><p>Medline generated $20.6 billion in net sales and $1 billion in profit over the first nine months of 2025, along with $2.7 billion in&nbsp;core profit. In 2024, the company brought in $25.5 billion in revenue and $1.2 billion in net income. Medline said its sales have grown every year since the company was founded, supported by a large base of recurring revenue.</p><p>Prime Vendor agreements accounted for $16 billion in net sales in 2024. Medline said its Prime Vendor retention rate has averaged more than 98% over the past five years.</p><h2 class="st-heading-2"><strong>Commercial Operations</strong></h2><p>The company maintains $4.5 billion in global inventory and operates a fleet of more than 2,000 MedTrans trucks. Medline’s U.S. commercial organization includes about 3,800 employees across sales, clinical support, customer service and supply chain roles.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Medline (MDLN) plans to sell 179 million Class A shares at $26 to $30 each. (Photo credit: Getty Images)

Medline Files For One Of 2025’s Largest IPOs With Potential Valuation Near $55.3B

Medline’s IPO plans outline a 179 million share offering at $26 to $30 with potential demand from major investors indicating a valuation near $55.3 billion.

Medline Announces Public Filing of Registration Statement with the SEC

Medline Announces Public Filing of Registration Statement with the SEC Medline Announces Public Filing of Registration Statement with the SEC PR Newswire NORTHFIELD, Ill., Oct. 28, 2025 NORTHFIELD...

Medline, Inc. engages in the provision of medical-surgical products and supply chain solutions. It operates through the Medline Brand and Supply Chain Solutions segments. The Medline Brand segment is involved in the procurement and manufacture of products from surgical solutions, front line care, and laboratory and diagnostics categories. The Supply Chain Solutions segment focuses on procurement and distribution of a variety of third-party products from national brands and provides tailored logistics and supply chain optimization services to domestic and international consumers. The company was founded by Jim Mills and Jon Mills in 1966 and is headquartered in Northfield, IL.

Medline Inc - Ordinary Shares - Class A

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Stocktwits Polls

Medline Inc.

Traders discuss receiving unexpectedly small allocations of IPO shares, expressing frustration or surprise about the limited access to the new offering.

Discussions focus on the company's stock soaring immediately after its market debut, with many users noting the significant percentage gain from its IPO price and trading activity.

Investors share their long-term price targets and analysis for the company, often based on its business fundamentals, revenue growth, or market potential.

Skeptics caution against holding the stock, predicting a drop below its IPO price or highlighting concerns such as significant debt and potential for early investor exits.

Medline (MDLN) is trending following its significant public debut as one of the year's largest IPOs, driving overwhelmingly bullish sentiment within the community. Investors are actively discussing its potential for substantial price appreciation, driven by its strong market position as a leading medical supplies distributor, despite some debate regarding its debt profile.

Current Price	$40.60
Prev Close	$29.00
Open	$35.00
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	$1.52
Price to Book	N/A
Revenue Per Employee	$593,186.05
Enterprise Value/EBITDA	N/A

MDLN
Medline Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest MDLN News

MDLNMedline Inc.